A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 39/395 (2006.01)
Patent
CA 2656613
The invention relates to a method for the treatment of a disease susceptible to anti-EGFR treatment, comprising the step of administering, to a human being in nee thereof, a combination of an anti-EGFR agent and an anti-neutrophil-chemoattracta agent, wherein said anti-neutrophil-chemoattractant agent is administered in a dosag regimen that is sufficient to reduce one or more undesired dermatological side-effects the anti-EGFR agent. In one embodiment, the anti-EGFR agent is an anti-EGF antibody and the anti-neutrophil-chemoattractant agent is an anti-IL-8 antibody.
L'invention concerne un procédé pour le traitement d'une maladie sensible au traitement anti-EGFR, comprenant l'étape consistant à administrer, à un être humain en ayant besoin, une combinaison d'un agent anti-EGFR et d'un agent anti-chimioattractif neutrophile, ledit agent anti-chimioattractif neutrophile étant administré en un régime de dosage qui est suffisant pour réduire un ou plusieurs effets secondaires dermatologiques non désirés de l'agent anti-EGFR. Dans un mode de réalisation, l'agent anti-EGFR est un anticorps anti-EGF et l'agent anti-chimioattractif neutrophile est un anticorps anti-IL-8.
Baadsgaard Ole
Edvardsen Klaus
Lisby Steen
Borden Ladner Gervais Llp
Genmab A/s
LandOfFree
Prevention of rash in patients undergoing anti-egfr therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Prevention of rash in patients undergoing anti-egfr therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Prevention of rash in patients undergoing anti-egfr therapy will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1839953